Genetics of Marfan Syndrome Treatment & Management
- Author: Harold Chen, MD, MS, FAAP, FACMG; Chief Editor: Maria Descartes, MD more...
General measures for all adults with Marfan syndrome are as follows :
Moderate restriction of physical activity
Echocardiography at annual intervals
Key issues in cardiovascular management are as follows :
Beta-blocker therapy should be considered at any age if the aorta is dilated, but prophylactic treatment may be more effective in those with an aortic diameter of less than 4 cm.
Risk factors for aortic dissection include aortic diameter greater than 5 cm, aortic dilatation extending beyond the sinus of Valsalva, rapid rate of dilatation (45% per year, or 1.5 mm per y in adults), and family history of aortic dissection.
At least annual evaluation should be offered and should include clinical history, examination, and echocardiography.
In children, serial echocardiography at 6-month to 12-month intervals is recommended, and the frequency depends on the aortic diameter (in relation to body surface area) and the rate of increase.
Prophylactic aortic root surgery should be considered when the aortic diameter at the sinus of Valsalva is more than 5 cm.
Counseling for pregnancy is as follows :
Fifty percent risk for transmitting a pathogenic mutation to offspring
High-risk pregnancy with aortic root diameter of more than 40 mm or previous cardiovascular surgery or severe heart disease
Prepartum aortic root replacement with diameters of more than 40 mm
Serial echocardiography until 3 months postpartum
Beta-blockers are as follows:
Beta-adrenergic receptor antagonists have gained acceptance as potential agents for delaying aortic expansion and for delaying the progression to rupture or dissection.
The rate of surgical interventions has substantially declined during the past decade of beta-blockade use.
Beta-blocker therapy retards aortic growth in children and adolescents with Marfan syndrome.
A recent study concluded that data are not sufficient to recommend or discourage the use of beta-blockers in children with congestive heart failure. 
Calcium antagonist therapy also retards aortic growth, but a recommended dose has not been established.
The optimal age to begin beta-blockade therapy has not been determined. Some investigators begin therapy during infancy, but others wait until the aortic diameter exceeds the 95th percentile or a rapid rate of dilation is observed.
In asymptomatic patients, the elastic properties of the aortic root appear to have a heterogeneous response after long-term treatment with atenolol.
The stiffness index and distensibility are most likely to be useful when the baseline end-diastolic aortic root diameter is more than 40 mm.
More experience is needed to determine the optimal dose of beta-blockers to minimize growth of the aortic root.
ACE inhibitors are as follows[34, 35] :
ACE inhibitors reduce central arterial pressure and conduit arterial stiffness and may be useful in Marfan syndrome. This approach received support by a short-term, nonrandomized study comparing enalapril with beta blockade in which stiffness and rate of dilatation improved with the ACE inhibitors. 
Another study of patients with Marfan syndrome maintained on beta blockade examined the impact of adding an ACE inhibitor, perindopril, compared with placebo. Over a 24-week period, those receiving the ACE inhibitor had a reduction in aortic stiffness and less absolute change in aortic root dimensions. 
Matrix metalloproteinases (MMPs) are as follows[35, 37] :
Syndromes that resemble Marfan syndrome, especially in the potential for aneurysm and dissection, were found to be due to mutations in genes encoding TGFβ receptors. 
The potential importance of MMPs was stimulated by studies of non-Marfan syndrome abdominal aortic aneurysm in humans and thoracic aortic aneurysm in mice engineered to have Marfan syndrome, in both of which levels of MMP-2 and MMP-9 were raised. 
Doxycycline administration to a mouse model of Marfan syndrome suppressed MMPs and improved aortic wall architecture and stiffness compared with atenolol. 
Other therapy is as follows:
Anticoagulant medications such as warfarin are needed after artificial heart-valve placement.
Intravenous antibiotic therapy is required during cardiac and noncardiac procedures to prevent bacterial endocarditis.
Progesterone and estrogen therapy have been used to induce puberty and reduce the patient's ultimate height if hormonal treatment is begun before puberty, but no conclusive data are yet available to show whether this therapy reduces scoliosis.
Myopia is treatable with refraction.
Patients with flat feet may wear shoes with adequate arch support, although custom orthotics may be required. Guidelines for the diagnosis and treatment of pediatric flatfoot have been established. 
Psychological counseling is helpful for families coping with feelings of denial, anger, blame, depression, or guilt.
Future therapeutic strategies are as follows :
An ARB regimen is now recommended as first-line treatment and should be emphasized. Some cardiologists who specialize in Marfan syndrome also have their patients on beta blockers to cover both arms of the pathway. However, no studies have been published as yet to officially recommend the approach.
The current criterion standard for treatment of aortic aneurysm in Marfan syndrome is the preventive administration of beta-blockers. However, beta-blockers do not prevent surgery at a later age.
The discovery that TGFβ antagonism can rescue aortic aneurysm in C1039G/+ mice prompted the idea to test the efficacy of losartan, a widely used angiotensin II type I receptor (AT1) antagonist, because of its antihypertensive properties and ability to counteract TGFβ in animal models of chronic renal disease and cardiomyopathy.
Thus, TGFβ antagonism is a general strategy against aneurysm progression in patients with Marfan syndrome and other disorders of the TGFβ-signaling network.
Proof of the above principle was obtained by treating Marfan mice with TGF β- neutralizing antibody by intraperitoneal injection. 
In a preliminary observational study, 17 pediatric Marfan syndrome patients with progressive aortic enlargement despite optimal medical therapy were given an angiotensin receptor blocker agent and were followed for 12-42 months. Patients had a significant decrease in rate of change of aortic root dimension. This study provides the first evidence for a significant benefit of angiotensin receptor blocker use over current therapies in reducing aortic root dilation in severe pediatric Marfan syndrome.
A large, randomized clinical trial in Marfan syndrome patients was initiated and included a total of 608 patients in February 2011 that compares atenolol with losartan for a 3-year treatment.  Meanwhile, a nearly a dozen additional trials with different designs and inclusion criteria were initiated in Belgium, France, Italy, the Netherlands, Taiwan, and the United Kingdom. 
The results of the study by Pees et al have added insight regarding the beneficial effect of losartan as monotherapy, even in mild to moderate cases, in addition to the reported results in severely affected children and adolescents. 
Genetic counseling is discussed as follows :
Recurrence risk for the patient's siblings is small if neither parent is affected. Gonadal mosaicism is reported as the cause of multiple affected offspring being born to unaffected parents. Risk is 50% if one parent is affected.
Recurrence risk for the patient's offspring is 50% if the spouse is normal. Fifty percent Homozygous Marfan syndrome was reported in case of an affected spouse. Compound heterozygosity at the FBN1 locus was confirmed at the molecular level; the affected child had a severe phenotype, leading to early death.
During counseling, the variability of the disease should be emphasized because an affected child may be more or less affected than the parent.
Indications for prophylactic surgery of the aortic root in adults (at least one criterion)
Aortic root diameter of more than 55 mm (50 mm according to some authors) and aortic root diameter of more than 50 mm (45–50 mm according to some authors) in patients with high risk for aortic complications
- Family history for aortic dissection
- Growth of the aortic root of more than 10 mm/y
- Dilatation of the aortic sinus involving the ascending aorta
- More than mild aortic regurgitation
- Severe mitral regurgitation
- Before major noncardiovascular surgery
- Women planning pregnancy
Aortic ratio of more than 1.5
Ratio of the diameters of the aortic root and the descending aorta of more than 2
Indications for prophylactic surgery of the aortic root in children
If possible, surgery should be delayed until adolescence
Aortic root diameters with similar thresholds as in adults
Aortic root diameters outside the upper confidence interval deviate upward from the perused centile on follow-up echocardiograms
Cardiovascular surgery can substantially prolong survival. Prophylactic and emergency cardiovascular surgery is needed for treatment of aortic and mitral regurgitation, aortic aneurysm, and aortic dissection. Emergency surgical replacement of the aortic root is indicated for survivors of acute proximal aortic dissection.
The ascending aorta is usually replaced when the aorta exceeds 55-60 mm in diameter. Composite valve-graft replacement is performed, in which the dilated aortic segment is replaced by a prosthetic valve sewn into a tube graft with reimplantation of the coronary ostia (modified Bentall procedure). Composite valve-graft replacement of the aortic root has low rates of morbidity and mortality, produces excellent long-term results, and is currently the treatment of choice for proximal dissection or clinically significant annuloaortic ectasia in patients with Marfan syndrome.
An aortic valve–sparing procedure is evolving for patients with an aortic aneurysm and favorable characteristics of the aortic valve and annulus. The advantages of this procedure include the avoidance of anticoagulation and a lowered risk of thromboembolism and endocarditis. The aortic valve–sparing procedure is still controversial because of concerns that it poses a risk of progressive valvular degeneration and annular dilation. Additional long-term data are required before routine use of this procedure can be recommended
Severe scoliosis requires surgery. Bracing has a limited role in treating the most severe form of infantile scoliosis.
Surgery should not be performed on a child younger than 4 years because many patients with large curves before this age spontaneously die of cardiac complications. Results of spinal fusion are better in children older than 5 years.
Indications for surgery in adults include pain, neurologic signs, and thoracic curves greater than 45°, which can cause restrictive lung disease
Protrusio acetabuli surgery: This is directed at arresting progression, relieving pain, and restoring the function of the hip through hip replacement with bone grafting of the medial acetabular cavity in older patients and closure of the tri-iradiate cartilage in a child or adolescent.
The shape of the front of the thorax becomes stable and established by mid adolescence. Therefore, repair of pectus excavatum to improve respiratory mechanics should be delayed until then to lessen the risk of recurrence.
Pectus carinatum repair is mainly performed for cosmetic reasons
A chest tube is an appropriate initial therapy.
After one recurrence, a more aggressive approach involving bleb resection and pleurodesis is recommended.
Lasers can be used to restore a detached retina.
The risk of retinal detachment related to lens extraction is increased. The lens is removed only in the following few instances:
- Dislocation of a lens in the anterior chamber, especially when it touches the corneal endothelium
- Significant lens opacity
- Evidence of lens-induced uveitis and glaucoma
- Inadequate visual acuity that is not correctable by refraction and iris manipulation
- Imminent complete luxation of the lens
Consultations may include the following:
No special diet is needed.
In general, patients can remain fully active unless their symptoms limit them. Patients should be discouraged from participating in demanding sports because several highly trained athletes with unrecognized Marfan syndrome have suddenly died from ruptured aortic aneurysms.
Competitive and contact sports are potentially dangerous because of underlying aortic weakness and dilatation, valvular insufficiency, ocular abnormalities, and skeletal problems. Patients should avoid blows to the head (eg, in boxing, high diving) and to protect themselves against blows to the globe (racquet sports) with cushioned spectacles.
To protect against pneumothorax, patients should avoid the rapid decompression associated with quick ascents in elevators, scuba diving, and flying in unpressurized aircraft.
Patients should avoid activities involving isometric work such as weightlifting, climbing steep inclines, participating in gymnastics, and performing pull-ups. These exercises cause excessive elevations of systolic blood pressure and may lead to sudden death.
Nonstrenuous activities and sports (eg, golf, walking, fishing) are recommended. Appropriate exercise is physically and emotionally beneficial.
Bolar N, Van Laer L, Loeys BL. Marfan syndrome: from gene to therapy. Curr Opin Pediatr. 2012 Aug. 24(4):498-504. [Medline].
Loeys BL, Chen J, Neptune ER, et al. A syndrome of altered cardiovascular, craniofacial, neurocognitive and skeletal development caused by mutations in TGFBR1 or TGFBR2. Nat Genet. 2005 Mar. 37(3):275-81. [Medline].
Lee B, Godfrey M, Vitale E, et al. Linkage of Marfan syndrome and a phenotypically related disorder to two different fibrillin genes. Nature. 1991. 352:337-339.
Pyeritz RE. The Marfan syndrome. Annu Rev Med. 2000. 51:481-510. [Medline].
Rose PS, Levy HP, Ahn NU, et al. A comparison of the Berlin and Ghent nosologies and the influence of dural ectasia in the diagnosis of Marfan syndrome. Genet Med. 2000 Oct. 2(5):278-82. [Medline].
Loeys BL, Dietz HC, Braverman AC, et al. The revised Ghent nosology for the Marfan syndrome. J Med Genet. 2010 Jul. 47(7):476-85. [Medline].
Faivre L, Collod-Beroud G, Ades L, et al. The new Ghent criteria for Marfan syndrome: what do they change?. Clin Genet. 2012 May. 81(5):433-42. [Medline].
Van de Velde S, Fillman R, Yandow S. Protrusio acetabuli in Marfan syndrome. History, diagnosis, and treatment. J Bone Joint Surg Am. 2006 Mar. 88(3):639-46. [Medline].
Jones KB, Sponseller PD, Erkula G, et al. Symposium on the musculoskeletal aspects of Marfan syndrome: meeting report and state of the science. J Orthop Res. 2007 Mar. 25(3):413-22. [Medline].
Lacassie HJ, Millar S, Leithe LG, et al. Dural ectasia: a likely cause of inadequate spinal anaesthesia in two parturients with Marfan's syndrome. Br J Anaesth. 2005 Apr. 94(4):500-4. [Medline].
Dean JC. Marfan syndrome: clinical diagnosis and management. Eur J Hum Genet. 2007 May 9. [Medline].
Tiecke F, Katzke S, Booms P, et al. Classic, atypically severe andneonatal Marfan syndrome: twelve mutations and genotype-phenotypecorrelations in FBN1 exons 24-40. Eur J Hum Genet. 2001. 9:13-21. [Medline]. [Full Text].
de Vries BB, Pals G, Odink R, Hamel BC. Homozygosity for a FBN1 missense mutation: clinical and molecular evidence for recessive Marfan syndrome. Eur J Hum Genet. 2007 Sep. 15(9):930-5. [Medline].
Pyeritz RE. Evaluation of the adolescent or adult with some features of Marfan syndrome. Genet Med. 2012 Jan. 14(1):171-7. [Medline].
Gupta PA, Wallis DD, Chin TO, et al. FBN2 mutation associated with manifestations of Marfan syndrome and congenital contractural arachnodactyly. J Med Genet. 2004 May. 41(5):e56. [Medline].
Putnam EA, Zhang H, Ramirez F, Milewicz DM. Fibrillin-2 (FBN2) mutations result in the Marfan-like disorder, congenital contractural arachnodactyly. Nat Genet. 1995 Dec. 11(4):456-8. [Medline].
Callewaert B, Malfait F, Loeys B, De Paepe A. Ehlers-Danlos syndromes and Marfan syndrome. Best Pract Res Clin Rheumatol. 2008 Mar. 22(1):165-89. [Medline].
Zhu L, Vranckx R, Khau Van Kien P, et al. Mutations in myosin heavy chain 11 cause a syndrome associating thoracic aortic aneurysm/aortic dissection and patent ductus arteriosus. Nat Genet. 2006 Mar. 38(3):343-9. [Medline].
Loeys BL, Schwarze U, Holm T, et al. Aneurysm syndromes caused by mutations in the TGF-betareceptor. New Engl J Med. 2006. 355:788-798.
Glesby MJ, Pyeritz RE. Association of mitral valve prolapse and systemic abnormalities of connective tissue. A phenotypic continuum. JAMA. 1989 Jul 28. 262(4):523-8. [Medline].
Montgomery RA, Geraghty MT, Bull E, Gelb BD, Johnson M, McIntosh I, et al. Multiple molecular mechanisms underlying subdiagnostic variants of Marfan syndrome. Am J Hum Genet. 1998 Dec. 63(6):1703-11. [Medline].
Lieberman ER, Gomperts ED, Shaw KN, Landing BH, Donnell GN. Homocystinuria: clinical and pathologic review, with emphasis on thrombotic features, including pulmonary artery thrombosis. Perspect Pediatr Pathol. 1993. 17:125-47. [Medline].
Sood S, Eldadah ZA, Krause WL, McIntosh I, Dietz HC. Mutation in fibrillin-1 and the Marfanoid-craniosynostosis (Shprintzen-Goldberg) syndrome. Nat Genet. 1996 Feb. 12(2):209-11. [Medline].
Raymond FL, Tarpey PS, Edkins S, et al. Mutations in ZDHHC9, which encodes a palmitoyltransferase of NRAS and HRAS, cause X-linked mental retardation associated with a Marfanoid habitus. Am J Hum Genet. 2007 May. 80(5):982-7. [Medline].
Schwartz CE, Tarpey PS, Lubs HA, et al. The original Lujan syndrome family has a novel missense mutation (p.N1007S) in the MED12 gene. J Med Genet. 2007 Jul. 44(7):472-7. [Medline].
Faivre L, Masurel-Paulet A, Collod-Béroud G, Callewaert BL, Child AH, Stheneur C, et al. Clinical and molecular study of 320 children with Marfan syndrome and related type I fibrillinopathies in a series of 1009 probands with pathogenic FBN1 mutations. Pediatrics. 2009 Jan. 123(1):391-8. [Medline].
von Kodolitsch Y, Robinson PN. Marfan syndrome: an update of genetics, medical and surgical management. Heart. 2007 Jun. 93(6):755-60. [Medline].
Frobel AK, Hulpke-Wette M, Schmidt KG, Laer S. Beta-blockers for congestive heart failure in children. Cochrane Database Syst Rev. 2009 Jan 21. CD007037. [Medline].
Williams A, Davies S, Stuart AG, Wilson DG, Fraser AG. Medical treatment of Marfan syndrome: a time for change. Heart. 2008 Apr. 94(4):414-21. [Medline].
Pyeritz RE. Marfan syndrome: 30 years of research equals 30 years of additional life expectancy. Heart. 2009 Mar. 95(3):173-5. [Medline].
Yetman AT, Bornemeier RA, McCrindle BW. Usefulness of enalapril versus propranolol or atenolol for prevention of aortic dilation in patients with the Marfan syndrome. Am J Cardiol. 2005 May 1. 95(9):1125-7. [Medline].
Ahimastos AA, Aggarwal A, D'Orsa KM, et al. Effect of perindopril on large artery stiffness and aortic root diameter in patients with Marfan syndrome: a randomized controlled trial. JAMA. 2007 Oct 3. 298(13):1539-47. [Medline].
Chung AW, Yang HH, Radomski MW, van Breemen C. Long-term doxycycline is more effective than atenolol to prevent thoracic aortic aneurysm in marfan syndrome through the inhibition of matrix metalloproteinase-2 and -9. Circ Res. 2008 Apr 25. 102(8):e73-85. [Medline].
Chung AW, Au Yeung K, Sandor GG, Judge DP, Dietz HC, van Breemen C. Loss of elastic fiber integrity and reduction of vascular smooth muscle contraction resulting from the upregulated activities of matrix metalloproteinase-2 and -9 in the thoracic aortic aneurysm in Marfan syndrome. Circ Res. 2007 Aug 31. 101(5):512-22. [Medline].
Kharrazi FD, Rodgers WB, Coran DL, Kasser JR, Hall JE. Protrusio acetabuli and bilateral basicervical femoral neck fractures in a patient with Marfan syndrome. Am J Orthop. 1997 Oct. 26(10):689-91. [Medline].
[Guideline] Harris EJ, Vanore JV, Thomas JL, et al. Diagnosis and treatment of pediatric flatfoot. J Foot Ankle Surg. 2004 Nov-Dec. 43(6):341-73. [Medline].
Brooke BS, Habashi JP, Judge DP, Patel N, Loeys B, Dietz HC 3rd. Angiotensin II blockade and aortic-root dilation in Marfan's syndrome. N Engl J Med. 2008 Jun 26. 358(26):2787-95. [Medline]. [Full Text].
Pees C, Laccone F, Hagl M, Debrauwer V, Moser E, Michel-Behnke I. Usefulness of losartan on the size of the ascending aorta in an unselected cohort of children, adolescents, and young adults with Marfan syndrome. Am J Cardiol. 2013 Nov 1. 112 (9):1477-83. [Medline].
Chen H. Genetic Diagnosis and Counseling. 2nd ed. New York, NY: Springer; 2012. Vol 2: 1309-26.
Stout M. The Marfan syndrome: implications for athletes and their echocardiographic assessment. Echocardiography. 2009 Oct. 26(9):1075-81. [Medline].
Ageno W, Crotti S, Turpie AG. The safety of antithrombotic therapy during pregnancy. Expert Opin Drug Saf. 2004 Mar. 3(2):113-8. [Medline].
Meijboom LJ, Vos FE, Timmermans J, Boers GH, Zwinderman AH, Mulder BJ. Pregnancy and aortic root growth in the Marfan syndrome: a prospective study. Eur Heart J. 2005 May. 26(9):914-20. [Medline].
Goland S, Elkayam U. Cardiovascular problems in pregnant women with marfan syndrome. Circulation. 2009 Feb 3. 119(4):619-23. [Medline].
Goland S, Barakat M, Khatri N, Elkayam U. Pregnancy in Marfan syndrome: maternal and fetal risk and recommendations for patient assessment and management. Cardiol Rev. 2009 Nov-Dec. 17(6):253-62. [Medline].
Boileau C, Jondeau G, Mizuguchi T, Matsumoto N. Molecular genetics of Marfan syndrome. Curr Opin Cardiol. 2005 May. 20(3):194-200. [Medline].
Brooke BS, Habashi JP, Judge DP, Patel N, Loeys B, Dietz HC 3rd. Angiotensin II blockade and aortic-root dilation in Marfan's syndrome. N Engl J Med. 2008 Jun 26. 358(26):2787-95. [Medline].
Chen H. Marfan syndrome. Atlas of Genetic Diagnosis and Counseling. Totowa, New Jersey: Humana Press; 2006. 619-629.
Dagoneau N, Benoist-Lasselin C, Huber C, et al. ADAMTS10 mutations in autosomal recessive Weill-Marchesani syndrome. Am J Hum Genet. 2004 Nov. 75(5):801-6. [Medline].
Demetracopoulos CA, Sponseller PD. Spinal deformities in Marfan syndrome. Orthop Clin North Am. 2007 Oct. 38(4):563-72, vii. [Medline].
Gelb BD. Marfan's syndrome and related disorders--more tightly connected than we thought. N Engl J Med. 2006 Aug 24. 355(8):841-4. [Medline].
Ha HI, Seo JB, Lee SH, Kang JW, Goo HW, Lim TH, et al. Imaging of Marfan syndrome: multisystemic manifestations. Radiographics. 2007 Jul-Aug. 27(4):989-1004. [Medline].
Habashi JP, Judge DP, Holm TM, et al. Losartan, an AT1 antagonist, prevents aortic aneurysm in a mouse model of Marfan syndrome. Science. 2006 Apr 7. 312(5770):117-21. [Medline].
Habermann CR, Weiss F, Schoder V, et al. MR evaluation of dural ectasia in Marfan syndrome: reassessment of the established criteria in children, adolescents, and young adults. Radiology. 2005 Feb. 234(2):535-41. [Medline].
Lacro RV, Dietz HC, Wruck LM, et al. Rationale and design of a randomized clinical trial of beta-blocker therapy (atenolol) versus angiotensin II receptor blocker therapy (losartan) in individuals with Marfan syndrome. Am Heart J. 2007 Oct. 154(4):624-31. [Medline].
Ladouceur M, Fermanian C, Lupoglazoff JM, et al. Effect of beta-blockade on ascending aortic dilatation in children with the Marfan syndrome. Am J Cardiol. 2007 Feb 1. 99(3):406-9. [Medline].
Marfan AB. Un cas de deformation congenitale des quatre membres plus prononcee aux extremites caracterisee par l'allongement des os avec un certain degre d'amincissement. Bull Mem Soc Med Hop Paris (ser 3). 1896. 13:220-6.
Mizuguchi T, Collod-Beroud G, Akiyama T, et al. Heterozygous TGFBR2 mutations in Marfan syndrome. Nat Genet. 2004 Aug. 36(8):855-60. [Medline].
Mohamed SA, Aherrahrou Z, Liptau H, et al. Novel missense mutations (p.T596M and p.P1797H) in NOTCH1 in patients with bicuspid aortic valve. Biochem Biophys Res Commun. 2006 Jul 14. 345(4):1460-5. [Medline].
Nemet AY, Assia EI, Apple DJ, Barequet IS. Current concepts of ocular manifestations in Marfan syndrome. Surv Ophthalmol. 2006 Nov-Dec. 51(6):561-75. [Medline].
Nollen GJ, Mulder BJ. What is new in the Marfan syndrome?. Int J Cardiol. 2004 Dec. 97 Suppl 1:103-8. [Medline].
Pearson GD, Devereux R, Loeys B, et al. Report of the National Heart, Lung, and Blood Institute and National Marfan Foundation Working Group on research in Marfan syndrome and related disorders. Circulation. 2008 Aug 12. 118(7):785-91. [Medline].
Ramirez F, Dietz HC. Marfan syndrome: from molecular pathogenesis to clinical treatment. Curr Opin Genet Dev. 2007 Apr 26. [Medline].
Robinson PN, Arteaga-Solis E, Baldock C, et al. The molecular genetics of Marfan syndrome and related disorders. J Med Genet. 2006 Oct. 43(10):769-87. [Medline].
Spits C, De Rycke M, Van Ranst N, et al. Preimplantation genetic diagnosis for cancer predisposition syndromes. Prenat Diagn. 2007 May. 27(5):447-56. [Medline].
Stuart AG, Williams A. Marfan's syndrome and the heart. Arch Dis Child. 2007 Apr. 92(4):351-6. [Medline].
Summers KM, West JA, Peterson MM, et al. Challenges in the diagnosis of Marfan syndrome. Med J Aust. 2006 Jun 19. 184(12):627-31. [Medline].
Weigang E, Ghanem N, Chang XC, et al. Evaluation of three different measurement methods for dural ectasia in Marfan syndrome. Clin Radiol. 2006 Nov. 61(11):971-8. [Medline].